Author

J. Zahradnik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 11 Biochemistry· 3 Bioengineering· 1 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 15 Approach:experimental assay· 13 Organism:human· 9 Organism:virus· 5 Assay:proteomics· 4 Approach:statistical model· 4 Research Focus:drug response / drug discovery· 3 Approach:comparative / phylogenetic analysis· 2

Frequent Co-Authors

G. Schreiber· 13 shared K. Uriu· 11 shared The Genotype to Phenotype Japan (G2P-Japan) Consortium· 11 shared J. Ito· 10 shared Y. Kosugi· 10 shared K. Sato· 9 shared H. Nasser· 8 shared A. Saito· 7 shared

Activity by Year

2020-2023 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

13 shared papersMicrobiology

G. Schreiber

Mutual co-authors in cluster

Author profile →

17 papers

Recent·Most cited

Virological characteristics of the SARS-CoV-2 JN.1 variant

Y. Kaku, K. Okumura, M. Padilla-Blanco, Y. Kosugi, K. Uriu, A. A. Hinay, L. Chen, A. Plianchaisuk, K. Kobiyama, K. J. Ishii, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Zahradnik, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 JN.1 variant, focusing on its mutations and potential immune evasion capabilities.

bioRxiv · Dec 8, 2023Microbiology

Virological characteristics of the SARS-CoV-2 BA.2.86 variant

T. Tamura, K. Mizuma, H. Nasser, S. Deguchi, M. Padilla-Blanco, K. Uriu, J. E. M. Tolentino, S. Tsujino, R. Suzuki, I. Kojima, N. Nao, R. Shimizu, M. Jonathan, Y. Kosugi, Z. Guo, , K. Sato

This study investigates the virological characteristics of the SARS-CoV-2 BA.2.86 variant, finding it has higher reproduction number than EG.5.1 but lower pathogenicity and replication capacity compared to BA.2.

bioRxiv · Nov 2, 2023Microbiology

RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

M. Gagne, B. J. Flynn, C. C. Honeycutt, D. R. Flebbe, S. F. Andrew, S. J. Provost, L. McCormick, A. Van Ry, E. McCarthy, J.-P. M. Todd, S. Bao, I.-T. Teng, S. Marciano, Y. Rudich, C. Li, , D. C. Douek

RBD-62, a high-affinity ACE2 antagonist, limits SARS-CoV-2 replication in both upper and lower airways in rhesus macaques without blocking memory responses or causing anti-drug immunity.

bioRxiv · Jun 9, 2023 · PreprintImmunology

Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variant

D. Yamasoba, K. Uriu, A. Plianchaisuk, Y. Kosugi, L. Pan, J. Zahradnik, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Ito, K. Sato

This study characterizes the virological features of the SARS-CoV-2 Omicron XBB.1.16 variant, showing increased transmissibility and immune evasion compared to previous variants.

The Lancet Infectious Diseases · Jun 1, 2023Peer-reviewedMicrobiology

Engineering dynamic gates in binding pocket of penicillin G acylase to selectively degrade bacterial signaling molecules

M. Grulich, B. Surpeta, A. Palyzova, H. Maresova, J. Zahradnik, J. Brezovsky

This paper designs engineered variants of penicillin G acylase to selectively degrade bacterial signaling molecules, showing significant shifts in substrate specificity.

bioRxiv · May 9, 2023 · PreprintBiochemistry

Enhanced transmissibility, infectivity and immune resistance of the SARS-CoV-2 Omicron XBB.1.5 variant

K. Uriu, J. Ito, J. Zahradnik, S. Fujita, Y. Kosugi, G. Schreiber, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study evaluates the transmissibility, infectivity, and immune resistance of the SARS-CoV-2 Omicron XBB.1.5 variant, finding it more transmissible and resistant than previous variants.

bioRxiv · Jan 16, 2023Microbiology

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

T. Tamura, J. Ito, K. Uriu, J. Zahradnik, I. Kida, H. Nasser, M. Shofa, Y. Oda, S. Lytras, N. Nao, Y. Itakura, S. Deguchi, R. Suzuki, L. Wang, M. M. Begum, , K. Sato

This study identifies XBB as a SARS-CoV-2 variant resulting from recombination of BA.2 subvariants, showing increased resistance to neutralizing antibodies and enhanced fusogenicity compared to BA.2.75.

bioRxiv · Dec 27, 2022 · PreprintMicrobiology

Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

J. Ito, R. Suzuki, K. Uriu, Y. Itakura, J. Zahradnik, S. Deguchi, L. Wang, S. Lytras, T. Tamura, I. Kida, H. Nasser, M. Shofa, M. M. Begum, M. Tsuda, Y. Oda, , K. Sato

The paper investigates convergent evolution in SARS-CoV-2 Omicron subvariants, identifying five critical spike protein substitutions in BQ.1.1 that enhance viral fitness and antibody resistance.

bioRxiv · Dec 5, 2022Microbiology

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75

A. Saito, T. Tamura, J. Zahradnik, S. Deguchi, K. Tabata, I. Kimura, J. Ito, H. Nasser, M. Toyoda, K. Nagata, K. Uriu, Y. Kosugi, S. Fujita, D. Yamasoba, M. Shofa, , Kei Sato

This study investigates the virological characteristics of SARS-CoV-2 Omicron BA.2.75, finding it has higher transmissibility and pathogenicity compared to BA.2 and BA.5, but similar sensitivity to antiviral drugs.

bioRxiv · Jul 14, 2022Microbiology

Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5

I. Kimura, D. Yamasoba, T. Tamura, N. Nao, Y. Oda, S. Mitoma, J. Ito, H. Nasser, J. Zahradnik, K. Uriu, S. Fujita, Y. Kosugi, L. Wang, M. Tsuda, M. Kishimoto, , K. Sato

This study analyzes the virological characteristics of SARS-CoV-2 Omicron variants BA.2.12.1, BA.4, and BA.5, finding they have higher reproduction numbers, reduced neutralization by prior immunity, increased replication in lung cells, and greater pathogenicity in hamsters compared to BA.2.

bioRxiv · May 26, 2022Microbiology

SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant

I. Kimura, D. Yamasoba, H. Nasser, J. Zahradnik, Y. Kosugi, J. Wu, K. Nagata, K. Uriu, Y. L. Tanaka, J. Ito, R. Shimizu, T. S. Tan, E. P. Butlertanaka, H. Asakura, K. Sadamasu, , K. Sato

This study identifies the S375F mutation in the Omicron spike protein as responsible for its reduced cleavage efficiency, fusogenicity, and rapid spread.

bioRxiv · Apr 3, 2022Microbiology

Genetically engineered MRI-trackable extracellular vesicles as SARS-CoV-2 mimetics for mapping ACE2 binding in vivo

A. Galisova, J. Zahradnik, H. Allouche-Arnon, M. I. Morandi, P. Abou Karam, O. Avinoam, N. Regev-Rudzki, G. Schreiber, A. Bar-Shir

This paper develops MRI-trackable extracellular vesicles displaying SARS-CoV-2 RBD to map ACE2 binding in vivo and screen viral variants.

bioRxiv · Mar 27, 2022Bioengineering

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

SARS-CoV-2 convergent evolution as a guide to explore adaptive advantage

J. Zahradnik, J. Nunvar, G. Schreiber

This paper analyzes convergent evolution in SARS-CoV-2 spike protein mutations to identify adaptive advantages and understudied variants.

bioRxiv · May 24, 2021 · PreprintEvolutionary Biology

An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity

C. Motozono, M. Toyoda, J. Zahradnik, T. Ikeda, A. Saito, T. S. Tan, I. Ngare, H. Nasser, I. Kimura, K. Uriu, Y. Kosugi, S. Torii, A. Yonekawa, N. Shimono, Y. Nagasaki, , K. Sato

This study identifies two SARS-CoV-2 mutations, L452R and Y453F, that evade HLA-restricted cellular immunity and increase viral infectivity.

bioRxiv · Apr 2, 2021Microbiology

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor

J. Zahradnik, S. Marciano, M. Shemesh, E. Zoler, J. Chiaravalli, B. Meyer, Y. Rudich, O. Dym, N. Elad, G. Schreiber

The paper shows that in vitro evolved SARS-CoV-2 RBD mutations, like S477N, E484K, and N501Y, correlate with increased infectivity and are inhibited by high-affinity RBD drugs.

bioRxiv · Jan 6, 2021Biochemistry

An enhanced yeast display platform demonstrates the binding plasticity under various selection pressures

J. Zahradnik, D. Dey, S. Marciano, G. Schreiber

This paper enhances a yeast display platform with improved protein stability and fluorescence, demonstrating binding plasticity under different selection pressures.

bioRxiv · Dec 16, 2020 · PreprintBiochemistry